Loading...
Loading...
ORTX| Name | Value |
|---|---|
| Revenues | 7.3M |
| Cost of Revenue | 2.2M |
| Gross Profit | 5.1M |
| Operating Expense | 27.7M |
| Operating I/L | -22.6M |
| Other Income/Expense | 9.9M |
| Interest Income | 1.4M |
| Pretax | -12.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -12.3M |
Orchard Therapeutics plc is a biopharmaceutical company specializing in the development of gene therapies for rare and life-threatening diseases. The company's gene therapy approach involves transforming a patient's hematopoietic stem cells into a gene-modified cellular drug product, offering a potential one-time treatment for various conditions. Their product portfolio includes Strimvelis for adenosine deaminase-severe combined immunodeficiency (ADA-SCID) and a range of clinical development and preclinical programs targeting diseases such as metachromatic leukodystrophy, Wiskott-Aldrich syndrome, chronic granulomatous disease, and beta-thalassemia.
